Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa
- 1 August 1999
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 13 (12) , 1543-1547
- https://doi.org/10.1097/00002030-199908200-00015
Abstract
: To determine post-treatment relapse and mortality rates among HIV-infected and uninfected patients with tuberculosis treated with a twice-weekly drug regimen under direct observation (DOT). : Hlabisa, South Africa. : A group of 403 patients with tuberculosis (53% HIV infected) cured following treatment with isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E) given in hospital (median 17 days), followed by HRZE twice weekly to 2 months and HR twice weekly to 6 months in the community under DOT. : Relapses were identified through hospital readmission and 6-monthly home visits. Relapse (culture for Mycobacterium tuberculosis) and mortality given as rates per 100 person-years observation (PYO) stratified by HIV status and history of previous tuberculosis treatment. : Mean (SD) post-treatment follow-up was 1.2 (0.4) years (total PYO=499); 78 patients (19%) left the area, 58 (14%) died, 248 (62%) remained well and 19 (5%) relapsed. Relapse rates in HIV-infected and uninfected patients were 3.9 [95% confidence interval (CI) 1.5-6.3] and 3.6 (95% CI 1.1-6.1) per 100 PYO (P=0.7). Probability of relapse at 18 months was estimated as 5% in each group. Mortality was four-fold higher among HIV-infected patients (17.8 and 4.4 deaths per 100 PYO for HIV-infected and uninfected patients, respectively; P<0.0001). Probability of survival at 24 months was estimated as 59% and 81%, respectively. We observed no increase in relapse or mortality among previously treated patients compared with new patients. A positive smear at 2 months did not predict relapse or mortality. : Relapse rates are acceptably low following successful DOT with a twice weekly rifampicin-containing regimen, irrespective of HIV status and previous treatment history. Mortality is substantially increased among HIV-infected patients even following successful DOT and this requires further attention.Keywords
This publication has 8 references indexed in Scilit:
- Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South AfricaAIDS, 1999
- Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South AfricaBMJ, 1997
- Molecular epidemiology and transmission dynamics of Mycobacterium tuberculosis in rural AfricaTropical Medicine & International Health, 1997
- Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994.American Journal of Public Health, 1996
- Tuberculosis control in resource-poor countries: alternative approaches in the era of HIVThe Lancet, 1995
- Pulmonary Tuberculosis in HIV-Infected Patients in Zaire — A Controlled Trial of Treatment for Either 6 or 12 MonthsNew England Journal of Medicine, 1995
- High-compliance tuberculosis treatment programme in a rural communityThe Lancet, 1994
- Evaluation of New Anti-Infective Drugs for the Treatment and Prevention of TuberculosisClinical Infectious Diseases, 1992